Skip to main content

For decades the FTC has been warning people about online ports, portals, and pop-ups that can be conduits for questionable claims. But companies shouldn’t think we’ve taken our eye off another potential doorway for deception: direct mail. According to an FTC lawsuit, a group of seven U.S. and Canadian defendants used glossy magazine-style mailers to advertise that Neurocet, Regenify, and Resetigen-D could treat a list of diseases, maladies, and conditions long enough to fill Gray’s Anatomy – the book and the show.

Neurocet Regenify exhibitsThe defendants pitched Neurocet as an answer to the kinds of chronic pain that often besets older consumers, including arthritis, back pain, and headaches. What’s more, they promised that Neurocet provides relief that lasts 26 times longer than popular pain medications and is even stronger than morphine, leading to reduced inflammation and greater mobility and flexibility. And just to gild the pain relief lily, they said their claims were supported by scientific or clinical proof.

They advertised Regenify and Resetigen-D to repair cell damage everywhere in the body, turning back the clock on damage to skin, tissue, bones, and organs while also improving memory and brain function by as much as 97.4%. That’s just for starters. The ads also pitched the products as a treatment for arthritis, tinnitus, asthma, high cholesterol, psoriasis, and eczema. Oh, and users would lose weight and gain muscle.

Skeptical? Don’t be, implied the defendants. Ads for Regenify and Resetigen-D featured glowing testimonials from people who had supposedly tried the products. They also trotted out purported endorsements from gastroenterologists, neurologists, nephrologists, pulmonologists, cardiologists, rheumatologists, and pretty much every other kind of –ologist who’s ever donned a white coat.

The complaint charges the defendants with making “false or unsubstantiated claims.” Others might use stronger language to describe the practice of targeting older consumers in this fashion, especially considering the defendants didn’t have scientific support for their representations and used purported endorsements from medical professionals and consumers that were flat-out fictitious.

The proposed stipulated order puts provisions in place to protect consumers in the future and requires the defendants to turn over $1.3 million, which may be used for consumer refunds.

If you think you’ve seen a lot of cases from the FTC recently challenging misleading pain relief claims and deceptive treatments for maladies afflicting older Americans, you’re right – and there are good reasons why that’s the case. First, as the opioid crisis demonstrates, millions of people are desperate for relief from chronic pain. Second, with the Boomer Consumer demographic bump, more people are struggling with age-related medical conditions for which there are no easy cures. And third, the Venn diagram of those two groups overlaps substantially.

That’s why the FTC continues the fight against bogus treatments and cures, and why we wage the war regardless of whether marketers convey their questionable claims online, in direct mail, via telemarketing, or in social media.


It is your choice whether to submit a comment. If you do, you must create a user name, or we will not post your comment. The Federal Trade Commission Act authorizes this information collection for purposes of managing online comments. Comments and user names are part of the Federal Trade Commission’s (FTC) public records system, and user names also are part of the FTC’s computer user records system. We may routinely use these records as described in the FTC’s Privacy Act system notices. For more information on how the FTC handles information that we collect, please read our privacy policy.

The purpose of this blog and its comments section is to inform readers about Federal Trade Commission activity, and share information to help them avoid, report, and recover from fraud, scams, and bad business practices. Your thoughts, ideas, and concerns are welcome, and we encourage comments. But keep in mind, this is a moderated blog. We review all comments before they are posted, and we won’t post comments that don’t comply with our commenting policy. We expect commenters to treat each other and the blog writers with respect.

  • We won’t post off-topic comments, repeated identical comments, or comments that include sales pitches or promotions.
  • We won’t post comments that include vulgar messages, personal attacks by name, or offensive terms that target specific people or groups.
  • We won’t post threats, defamatory statements, or suggestions or encouragement of illegal activity.
  • We won’t post comments that include personal information, like Social Security numbers, account numbers, home addresses, and email addresses. To file a detailed report about a scam, go to

We don't edit comments to remove objectionable content, so please ensure that your comment contains none of the above. The comments posted on this blog become part of the public domain. To protect your privacy and the privacy of other people, please do not include personal information. Opinions in comments that appear in this blog belong to the individuals who expressed them. They do not belong to or represent views of the Federal Trade Commission.

Get Business Blog updates